MediciNova, Inc. — Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for unmet medical needs. The filing covers the quarter and six months ended June 30, 2011. The company had 15,285,706 common shares outstanding as of August 10, 2011 and no approved products or commercial product revenue.
The prioritized programs were MN-221 for acute asthma and COPD exacerbations and MN-166/AV411 (ibudilast) for multiple sclerosis and other central nervous system disorders. The company operated with 14 full-time employees following a January 2011 reduction-in-force.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2011 | Six Months Ended June 30, 2011 | Comparable Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $2.0 million | $4.7 million | $2.3 million and $5.3 million, respectively |
| General and administrative expense | $1.7 million | $4.0 million | $1.8 million and $4.1 million, respectively |
| Operating loss | $3.7 million | $8.7 million | $4.2 million and $9.4 million, respectively |
| Net loss | $4.7 million | $10.3 million | $4.3 million and $9.5 million, respectively |
| Net loss per share | $0.31 | $0.74 | $0.35 and $0.77, respectively |
| Net cash used in operating activities | Not separately provided | $9.4 million | $10.3 million |
At June 30, 2011, cash and cash equivalents were $11.9 million, compared with $28.3 million at December 31, 2010. Total assets were $27.2 million and total liabilities were $4.4 million. Stockholders’ equity was $22.7 million, and the accumulated deficit was $277.9 million.
The company had no debt at June 30, 2011. It repaid its $15.0 million Oxford loan on April 1, 2011 and the Avigen-related convertible notes matured on June 18, 2011. A $0.5 million write-off of debt-related costs was recorded in the first half. Operating margins and profitability ratios are not meaningful because revenue was zero.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense declined $0.6 million, primarily because COPD and bioavailability trials were completed and manufacturing costs decreased, partly offset by higher MN-221-CL-007 enrollment costs.
- Six-month general and administrative expense declined $0.1 million, mainly because of lower stock-based compensation following the reduction in headcount.
- Six-month net loss increased $0.8 million to $10.3 million, primarily due to the $0.5 million debt-cost write-off, higher interest expense from repayment of the Oxford loan, and lower interest income.
- Operating cash use improved by $0.9 million year over year, but cash declined $16.3 million during the first half because operating use and debt repayment exceeded financing proceeds.
- MediciNova raised approximately $7.9 million of net proceeds from a March underwritten offering of common-stock units and warrants. It also entered into a May at-the-market facility for up to $15.0 million; no shares had been sold under that facility through June 30.
- All restricted cash and related Avigen note obligations were settled or released following the June 18 maturity of the convertible notes.
Guidance, Outlook, Risks, and Unusual Items
- Management expected existing cash at June 30, 2011 to fund forecasted research and development expenses and fixed contractual obligations through June 30, 2012, but stated that additional financing or corporate partnerships would be needed by the first quarter of 2012 to maintain operations at the then-current level.
- The filing states that failure to obtain adequate funding would require further workforce reductions, additional cost controls, and delaying, reducing, or terminating development programs. Management disclosed that this situation raised substantial doubt about the company’s ability to continue as a going concern.
- MN-221-CL-007 enrollment had improved, and management expected to enroll the final patient by year-end 2011, although completion timing and costs remained uncertain because of emergency-room enrollment risks.
- Further significant MN-166/AV411 clinical development was generally deferred pending a strategic collaboration or additional funding.
- On June 29, 2011, the company signed an agreement with Zhejiang Medicine and Beijing Make-Friend Medicine Technology to form a China joint venture for MN-221. Ministry of Commerce approval had not yet been obtained.
- Subsequent events included a nine-month headquarters lease extension through May 31, 2012 at monthly base rent of $12,468 and an investigator-initiated, investigator-funded Phase 2 ibudilast trial for medication-overuse headache in Australia.
- A former employee sent a legal letter containing allegations that could threaten litigation. No loss range could be estimated, although management did not expect a material adverse financial statement effect.
- Primary risks include continued operating losses, financing and dilution risk, clinical-trial delays or failure, regulatory approval uncertainty, reliance on third-party contract research organizations and manufacturers, license-right termination risk, intellectual-property limitations, and dependence on strategic partners.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify the company’s near-term financing plans, actual cash burn, and whether the stated runway and going-concern assessment remain current.
- Track enrollment, completion timing, results, and remaining costs for the MN-221-CL-007 trial.
- Confirm Ministry of Commerce approval and operating terms for the China MN-221 joint venture.
- Review subsequent use of the $15.0 million at-the-market facility and potential equity dilution from outstanding warrants and options.
- Assess whether MediciNova has secured a strategic partner for MN-166/AV411 and whether development spending remains limited pending such a transaction.
- Review the status and potential exposure from the former-employee legal matter and other ordinary-course disputes.
- Evaluate the carrying values and future impairment risk of $9.6 million of goodwill and $4.8 million of in-process research and development.